Expertise that unites real-world evidence and patient access to improve outcomes.
UBC brings together seasoned professionals specializing in specialty therapies across risk management, evidence development, and patient access. Providing collaborative, expert-driven solutions tailored to your program, we are driven by a commitment to overcoming the barriers between your therapy and the patients that need it most. We leverage unrivaled expertise, real-world data and the latest technologies to provide the insights you need to mitigate risk, demonstrate long-term product value, ensure access, and support better patient outcomes.tis, pulvinar dapibus leo.
Insights
Breaking Barriers in Immuno-Oncology: Mechanistic Insights into Immune Checkpoint Inhibitor Resistance and Implications for Health Economics and Outcomes Research and Value Assessment
Immune checkpoint inhibitors deliver transformative outcomes, yet real‑world durability is often limited by primary and acquired resistance. This article explores the biological foundations of ICI resistance and outlines how integrating these insights into HEOR models can improve value assessment and real‑world decision‑making.
News
UBC Appoints Dr. Massoud Toussi as Vice President, Real World Evidence
UBC welcomes Massoud Toussi as its new Vice President of Real-World Evidence. Toussi brings over 20 years of experience spanning pharma, CROs, and regulatory work. He’s authored more than 50 publications and contributed to scientific standards through ENCePP, ISPE, ISPOR, and other key organizations.
Events
Outsourcing in Clinical Trials Southern California 2026
UBC is excited to join the conversation at OCT SoCal, to highlight our evidence development capabilities. We partner with sponsors to design registries, observational studies, and real‑world evidence strategies that inform regulatory and market access decisions. Meet with our team to learn how UBC supports high‑quality, data‑driven clinical and post‑market programs.
A Better Start to Therapy
With streamlined enrollment options and real-time capabilities, including purpose-built patient access technology solutions, UBC brings a “no patient left behind” approach to the start of therapy.
A Better Start to Therapy
With streamlined enrollment options and real-time capabilities, including purpose-built patient access technology solutions, UBC brings a “no patient left behind” approach to the start of therapy.
A Better Start to Therapy
With streamlined enrollment options and real-time capabilities, including purpose-built patient access technology solutions, UBC brings a “no patient left behind” approach to the start of therapy.
A Better Start to Therapy
With streamlined enrollment options and real-time capabilities, including purpose-built patient access technology solutions, UBC brings a “no patient left behind” approach to the start of therapy.
A Better Start to Therapy
With streamlined enrollment options and real-time capabilities, including purpose-built patient access technology solutions, UBC brings a “no patient left behind” approach to the start of therapy.
A Better Start to Therapy
With streamlined enrollment options and real-time capabilities, including purpose-built patient access technology solutions, UBC brings a “no patient left behind” approach to the start of therapy.
A Better Start to Therapy
With streamlined enrollment options and real-time capabilities, including purpose-built patient access technology solutions, UBC brings a “no patient left behind” approach to the start of therapy.
